Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT04348136
Active, not recruiting Phase 2/3

An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II

NCT04348136 · tracked via the Priya Life Science Japan tracker
Sponsor
JCR Pharmaceuticals Co., Ltd
Phase
Phase 2/3
Started
2019-09-01
Last updated
2026-09-03

Condition(s) studied

Mucopolysaccharidosis II

Investigational drug(s) / intervention(s)

JR-141 →

JR-141: IV infusion, 2.0 mg/kg/week

Study summary

Multicenter, open-label, single-group, designed to evaluate the long term efficacy and safety of study drug for the treatment of the MPS II.

Eligibility

Sex
MALE
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. A patient who participated in the preceding Study JR-141-301 and completed the Week 52 visit, and has no safety concerns to enter this study in the opinion of the investigator or subinvestigator. 2. A patient capable of providing written informed consent in person (However, this is not required for patients aged younger than 20 years at the time of consent or patients with intellectual disability associated with MPS II whose willingness cannot be verified.) 3. For patients aged younger than 20 years at the time of consent or patients with intellectual disability associated with MPS II whose willingness cannot be verified, written consent must be obtained from the legally acceptable representative. (Wherever possible, written consent of the patient should be obtained.) 4. Male patient whose partner is of child-bearing potential and agrees to use a medically accepted, highly effective method of contraception. Exclusion Criteria: 1. A patient who used any concomitant medication or therapy that could affect study assessments in the opinion of the investigator or subinvestigator. 2. A patient with a history of serious drug allergy or hypersensitivity that precludes participation in this study in the opinion of the investigator or subinvestigator. 3. A patient judged to be ineligible by the investigator or subinvestigator for other reasons.

Primary outcome measure(s)

  • Occurrence of adverse events — From the start of study (Week 52 of preceding study) up to the end of study, up to approximately 10.6 years
  • Occurrence of adverse reactions — From the start of study (Week 52 of preceding study) up to the end of study, up to approximately 10.6 years
  • Incidence of abnormal vital signs — Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
    Laboratory tests (hematology)
  • Incidence of abnormal vital signs — Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
    Laboratory tests (biochemistry)
  • Incidence of abnormal vital signs — Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
    Laboratory tests (iron-related tests)
  • Laboratory tests (urinalysis) — Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  • Vital signs (pulse rate) — Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  • Vital signs (body temperature) — Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  • Vital signs (blood pressure) — Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  • 12-lead electrocardiogram — Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
    The presence or absence of abnormal findings (if present, specific findings and whether or not they are reported as adverse events)
  • Antibody tests (anti-JR-141 antibodies) — Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  • IAR — From the start of study (Week 52 of preceding study) up to the end of study, up to approximately 10.6 years
  • Time course of developmental assessment data (Kyoto Scale of Psychological Development 2001) from initial dosing in the preceding study — Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  • Time course of developmental assessment data (Vineland-II) from initial dosing in the preceding study — Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  • Time course of developmental assessment data (Bayley-III or KABC-II) from initial dosing in the preceding study — Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  • Time course of CSF substrate (HS and DS) concentrations from initial dosing in the preceding study — Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  • Time course of serum HS and DS concentrations from initial dosing in the preceding study — Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  • Time course of urinary HS concentration from initial dosing in the preceding study — Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  • Time course of urinary DS concentration from initial dosing in the preceding study — Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  • Time course of uronic acid concentration from initial dosing in the preceding study — Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  • Time course of liver volume (assessed by CT or MRI) from initial dosing in the preceding study — Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  • Time course of spleen volume (assessed by CT or MRI) from initial dosing in the preceding study — Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  • Time course of cardiac function (assessed by echocardiography) from initial dosing in the preceding study — Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  • Time course of 6-minute walk test distance from initial dosing in the preceding study — Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
  • Time course of joint range of motion from initial dosing in the preceding study — Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years

Trial sites (20)

FacilityCityRegionStatus
Fukui Clinical site Fukui Japan
Fukuoka Clinical site 2 Fukuoka Japan
Fukuoka Clinical site Fukuoka Japan
Gifu Clinical site Gifu Japan
Hiroshima Prefectural Hospital Hiroshima Japan
Hokkaido Clinical site Hokkaido Japan
Kananagawa Ckinical site Kanagawa Japan
Kumamoto Clinical site Kumamoto Japan
Okayama Clinical site Okayama Japan
Okayama Clinical site 2 Okayama Japan
Okinawa Clinical site Okinawa Japan
Osaka Clinical site 3 Osaka Japan
Osaka Clinical site 2 Osaka Japan
Osaka Clinical site Osaka Japan
Saitama Clinical site Saitama Japan
Shizuoka Clinical site Shizuoka Japan
Shizuoka Clinical site 2 Shizuoka Japan
Tochigi Clinical site Tochigi Japan
Tokyo Clinical site Tokyo Japan
Tottori Clinical site Tottori Japan

More JCR Pharmaceuticals Co., Ltd. trials in Japan

An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04348136 on ClinicalTrials.gov ↗ ← All trials in Japan